Compare SELF & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | CING |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | 36 | 14 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 59.3M |
| IPO Year | 1997 | N/A |
| Metric | SELF | CING |
|---|---|---|
| Price | $5.10 | $4.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $34.50 |
| AVG Volume (30 Days) | 17.2K | ★ 237.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $12,705,245.00 | N/A |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $127.25 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.73 | $3.16 |
| 52 Week High | $5.63 | $11.89 |
| Indicator | SELF | CING |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 51.32 |
| Support Level | $5.01 | $4.20 |
| Resistance Level | $5.09 | $5.15 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.36 | 80.65 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.